KLTO, KLTOW · CIK 0001907223 · operating
Based in Omaha, Nebraska, Klotho Neurosciences develops gene therapy candidates targeting cancer, cardiovascular, and neurodegenerative diseases. The company's clinical pipeline includes KLTO-101, a gene therapy product for Alzheimer's disease treatment and prevention, and KLTO-202, a gene therapy candidate for amyotrophic lateral sclerosis (Lou Gehrig's disease) treatment and prevention. The company rebranded from Anew Medical, Inc. to Klotho Neurosciences in September 2024.
The company operates as a development-stage biopharmaceutical firm with a current workforce of three full-time employees. As a Nasdaq-listed entity, Klotho Neurosciences is pursuing a gene therapy approach to address significant unmet medical needs in neurological disease treatment. Revenue streams and commercialization timelines remain dependent on the advancement and regulatory approval of its product candidates through clinical development stages.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.32 | $-0.32 | — | |
| 2023 | — | — | — | |
| 2022 | — | — | — |